Background
Methods
Patients
DCIS | DCIS-Mi | ||
---|---|---|---|
Number of patients | 52 | 28 | |
Median follow-up period, months (range) | 62 (3–140) | 54 (14–182) | |
Median age, years (range) | 56 (36–86) | 50 (32–71) | |
Architectural classification | |||
comedo | 8 (15.4%) | 10(35.7%) |
P = 0.073 |
Papillary | 21 (40.4%) | 10 (35.7%) | (comedo vs others) |
cribriform | 15 (28.8%) | 4 (14.3%) | |
solid | 4 (7.7%) | 4 (14.3%) | |
low papillary | 4 (7.7%) | 0 (0) | |
Nuclear Grade | |||
Grade 1 | 21 (40.4%) | 7 (25) |
P = 0.16 |
Grade 2 | 29 (55.8%) | 18 (64.3) | (1 vs. 2,3) |
Grade 3 | 2 (3.9%) | 3 (10.7) | |
Necrosis | |||
absent | 25 (48.1%) | 4 (14.3%) |
P = 0.0017 |
Present | 27 (51.9%) | 24 (85.7%) | |
Van Nuys Classification* | |||
Grade 1 | 25 (48.1%) | 4 (14.3%) |
P = 0.0017 |
Grade 2 | 25 (48.1%) | 21 (75%) | (1 vs. 2,3) |
Grade 3 | 2 (3.9%) | 3 (10.7%) |
Immunohistochemistry
Antibody | Source | Clone | Dilution | Pretreatment | Citrate buffer | Incubation | Detection system |
---|---|---|---|---|---|---|---|
ER | DAKO | 1D5 | 1/50 | 4 × 15 min MW | pH6 | 1 h RT | ABC |
PgR | DAKO | 636 | 1/800 | 4 × 15 min MW | pH6 | 1 h RT | ABC |
HER2 | DAKO | 1/300 | 4 × 15 min MW | pH6 | 1 h RT | ABC | |
Ki-67 | DAKO | MIB-1 | 1/50 | 3 × 10 min MW | pH9 | 1 h RT | ABC |
Bcl-2 | DAKO | 124 | 1/50 | 3 × 10 min MW | pH9 | ON 4°C | En-Vision |
Bax | DAKO | 1/50 | 3 × 10 min MW | pH6 | ON 4°C | En-Vision | |
Survivin | SantaC | D-8 | 1/50 | 3 × 10 min MW | pH9 | 1 h RT | ABC |
p53 | DAKO | DO-7 | 1/50 | 3 × 10 min MW | pH9 | 1 h RT | ABC |
p21 | DAKO | SX118 | 1/25 | 3 × 10 min MW | pH9 | 1 h RT | ABC |
cyclinD1 | NovoC | P2D11F11 | 1/50 | 3 × 10 min MW | pH9 | 1 h RT | ABC |
Rb | NovoC | 13A10 | 1/100 | 3 × 10 min MW | pH6 | 1 h RT | ABC |
Evaluation of immunohistochemistry
Apoptosis
Statistical methods
Results
Histological evaluation
Relative expression of hormone receptors, HER2, and Ki-67: DCIS vs. DCIS-Mi
DCIS | DCIS-Mi |
P-value | |
---|---|---|---|
Estrogen Receptor | |||
positive | 38 (73.1%) | 19 (67.9%) | 0.62 |
negative | 14 (26.9%) | 9 (32.1%) | |
Progesterone Receptor | |||
positive | 37 (71.2%) | 16 (57.1%) | 0.21 |
Negative | 15 (28.9%) | 12 (42.9%) | |
c-erbB-2 | |||
0, 1+,2+ | 43 (82.7%) | 22 (78.6%) | 0.65 |
3+ | 9 (17.3%) | 6 (21.4%) | |
Ki-67 index | |||
positive rate % | 17.9 ± 1.5 | 22.8 ± 2.0 | 0.052 |
mean ± SD |
Relative expression of apoptosis-related markers: DCIS vs. DCIS-Mi
DCIS | DCIS-Mi |
P-value | |
---|---|---|---|
Apoptotic Index (N/1000) | 1.7 ± 0.4 | 2.9 ± 0.6 | 0.082 |
Bcl-2 | |||
negative | 21 (41.2%) | 6 (21.4%) | 0.071 |
Positive | 30 (58.8%) | 22 (78.6%) | |
Bax | |||
negative | 15 (28.8%) | 1 (3.6%) | 0.0028 |
Positive | 37 (71.2%) | 27 (96.4%) | |
Survivin | |||
negative | 23 (44.2%) | 4 (14.3%) | 0.0048 |
positive | 29 (55.8%) | 24 (85.7%) | |
p53 | |||
positive | 39 (76.5%) | 23 (82.1%) | 0.55 |
Negative | 12 (23.5%) | 5 (17.9%) | |
p21 | |||
positive | 36 (69.2%) | 15 (53.6%) | 0.17 |
negative | 16 (30.8%) | 13 (46.4%) | |
cyclinD1 | |||
positive | 36 (70.6%) | 18 (64.3%) | 0.57 |
Negative | 15 (29.4%) | 10 (35.7%) | |
Rb | |||
positive | 35 (68.6%) | 23 (82.1%) | 0.18 |
negative | 16 (31.4%) | 5 (17.9%) |
Apoptosis index | Survivin | Bax | |
---|---|---|---|
Bcl-2 | 0.11 | 0.65 | 0.042 |
Bax | 0.018 | 0.038 | - |
Survivin | 0.077 | - | - |
Univariate and multivariate analyses for factors affecting invasion
Univariate analysis | Multivariate analysis | |||||
---|---|---|---|---|---|---|
Odds ratio | 95% CI |
P-value | Odds ratio | 95% CI |
P-value | |
Necrosis (present vs. absent) | 5.56 | 1.84–20.91 | 0.0017 | 5.19 | 1.45–22.7 | 0.017 |
Apoptotic index (≧1000 of positive cells vs. < 1/1000) | 0.40 | 0.14–1.04 | 0.061 | 0.82 | 0.24–2.75 | 0.74 |
Ki-67 index (≧20% of positive cells vs. < 20%) | 0.44 | 0.15–1.18 | 0.10 | 0.89 | 0.24–3.24 | 0.86 |
Bcl-2 (positive vs. negative) | 2.57 | 0.93–7.95 | 0.071 | 3.49 | 1.04–13.3 | 0.051 |
Bax (positive vs. negative) | 10.92 | 2.02–203.9 | 0.0028 | 5.21 | 0.70–111.1 | 0.16 |
Survivin (positive vs. negative) | 4.76 | 1.57–17.9 | 0.0048 | 3.98 | 1.11–17.2 | 0.044 |